Hemab Therapeutics Reports Q1 Net Loss of $(22.7)M, EPS $(23.98) Post-IPO
COAG is trading near its 52-week low of $23 (14% above the low).
Summary
Hemab Therapeutics reported a Q1 2026 net loss of $(22.7) million and diluted EPS of $(23.98). This is the company's first public earnings report following its IPO in early May. While the net loss widened compared to the prior year, the company's earlier 8-K today confirmed that IPO proceeds provide a cash runway into 2029, which is critical for funding its ongoing clinical development programs.
At the time of this announcement, COAG was trading at $26.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $23.00 to $32.00. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Wiseek News.